What are the side effects of Avelumab?

Avelumab (Avelumab) is a programmed death ligand-1 (PD-L1) blocking antibody indicated for the treatment of patients with metastatic Merkel cell carcinoma (MCC); patients with advanced or metastatic urothelial carcinoma (UC); and in combination with axitinib for patients with advanced renal cell carcinoma (RCC). Avelumab targets the PD-L1 receptor, a protein receptor on the surface of cells. When avelumab blocks PD-L1, it "turns on" the ability of anti-cancer cells, such as T cells, to attack and kill tumors.

In clinical studies of avelumab, the most common adverse reactions (≥20%) in patients treated with avelumab were fatigue, musculoskeletal pain, infusion-related reactions, rash, urinary tract infection, nausea, constipation, cough, and diarrhea; the most common adverse reactions (≥20%) in patients treated with axitinib were Common adverse reactions (≥20%) include diarrhea, fatigue, hypertension, musculoskeletal pain, nausea, mucositis, palmar and plantar red blood cell paresthesia, dysphonia, decreased appetite, hypothyroidism, rash, hepatotoxicity, cough, dyspnea, abdominal pain, and headache. There are also warnings and precautions regarding serious and fatal immune-mediated adverse reactions, infusion-related reactions, complications of allogeneicHSCT, major cardiovascular adverse events, embryo-fetal toxicity, etc.

Avelumab is an emerging cancer treatment drug. The original drug has not yet been marketed in China, so it cannot be included in medical insurance. The price of Avelumab's generic drug, 200mg/10mL per box, may be more than RMB 10,000 per box (the price may fluctuate due to the exchange rate). We are not aware of any Avelumab generics being produced and put on the market. For specific prices and drug details, please consult Yade's medical consultant.